AU2020350745B2 - Fused pyridone compound, and preparation method therefor and use thereof - Google Patents
Fused pyridone compound, and preparation method therefor and use thereofInfo
- Publication number
- AU2020350745B2 AU2020350745B2 AU2020350745A AU2020350745A AU2020350745B2 AU 2020350745 B2 AU2020350745 B2 AU 2020350745B2 AU 2020350745 A AU2020350745 A AU 2020350745A AU 2020350745 A AU2020350745 A AU 2020350745A AU 2020350745 B2 AU2020350745 B2 AU 2020350745B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- membered heterocycloalkyl
- cycloalkyl
- compound
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910892032 | 2019-09-20 | ||
| CN201910892032.X | 2019-09-20 | ||
| CN201911129688.2 | 2019-11-18 | ||
| CN201911129688 | 2019-11-18 | ||
| CN201911157939 | 2019-11-22 | ||
| CN201911157939.8 | 2019-11-22 | ||
| CN202010054188 | 2020-01-17 | ||
| CN202010054188.3 | 2020-01-17 | ||
| CN202010102546 | 2020-02-19 | ||
| CN202010102546.3 | 2020-02-19 | ||
| CN202010230303 | 2020-03-27 | ||
| CN202010230303.8 | 2020-03-27 | ||
| CN202010306926 | 2020-04-17 | ||
| CN202010306926.9 | 2020-04-17 | ||
| CN202010367694 | 2020-04-30 | ||
| CN202010367694.8 | 2020-04-30 | ||
| CN202010967317.8 | 2020-09-15 | ||
| CN202010967317 | 2020-09-15 | ||
| PCT/CN2020/116510 WO2021052499A1 (zh) | 2019-09-20 | 2020-09-21 | 稠合吡啶酮类化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020350745A1 AU2020350745A1 (en) | 2022-04-07 |
| AU2020350745B2 true AU2020350745B2 (en) | 2026-03-26 |
Family
ID=74883935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020350745A Active AU2020350745B2 (en) | 2019-09-20 | 2020-09-21 | Fused pyridone compound, and preparation method therefor and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220389029A1 (https=) |
| EP (1) | EP4043464A4 (https=) |
| JP (1) | JP7642619B2 (https=) |
| KR (1) | KR20220086573A (https=) |
| CN (5) | CN118619971A (https=) |
| AU (1) | AU2020350745B2 (https=) |
| BR (1) | BR112022005193A2 (https=) |
| CA (1) | CA3155066A1 (https=) |
| CL (1) | CL2022000666A1 (https=) |
| CO (1) | CO2022004686A2 (https=) |
| IL (1) | IL291467B1 (https=) |
| MX (1) | MX2022003401A (https=) |
| PH (1) | PH12022550681A1 (https=) |
| TW (1) | TWI761961B (https=) |
| WO (1) | WO2021052499A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| WO2020231990A1 (en) | 2019-05-13 | 2020-11-19 | Relay Therapeutics, Inc. | Fgfr inhibitors and methods of use thereof |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| JP7601869B2 (ja) * | 2019-10-30 | 2024-12-17 | ▲勁▼方医▲薬▼科技（上海）有限公司 | 置換された複素環－環系化合物、その調製方法及び医薬への応用 |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2021197499A1 (zh) * | 2020-04-03 | 2021-10-07 | 南京明德新药研发有限公司 | 八氢吡嗪并二氮杂萘啶二酮类化生物 |
| WO2022037630A1 (zh) * | 2020-08-21 | 2022-02-24 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法及其医药上的用途 |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202233625A (zh) | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022143995A1 (zh) * | 2020-12-31 | 2022-07-07 | 正大天晴药业集团股份有限公司 | 四环类化合物及其医药用途 |
| CN116964056B (zh) * | 2021-03-25 | 2026-04-10 | 上海济煜医药科技股份有限公司 | 稠合吡啶酮类化合物盐型、晶型及其应用 |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| CN116848111A (zh) * | 2021-03-26 | 2023-10-03 | 浙江海正药业股份有限公司 | 一种kras抑制剂关键中间体及其制备方法 |
| CN116113632B (zh) * | 2021-03-30 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| WO2022223037A1 (zh) * | 2021-04-22 | 2022-10-27 | 劲方医药科技(上海)有限公司 | Kras抑制剂的盐或多晶型物 |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| CN117222654A (zh) * | 2021-09-06 | 2023-12-12 | 苏州赞荣医药科技有限公司 | Kras g12c抑制剂和其用途 |
| WO2023116895A1 (zh) * | 2021-12-24 | 2023-06-29 | 劲方医药科技(上海)有限公司 | Kras抑制剂的多晶型物及其制备方法和用途 |
| CN121466307A (zh) * | 2022-04-01 | 2026-02-06 | 劲方医药科技(上海)股份有限公司 | 药物组合物、其用途及癌症的治疗方法 |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2025016436A1 (zh) * | 2023-07-19 | 2025-01-23 | 上海济煜医药科技有限公司 | Kras抑制剂的制备方法、其中间体和其中间体的制备方法 |
| CN121773111A (zh) * | 2023-08-15 | 2026-03-31 | 劲方医药科技(上海)股份有限公司 | 吡嗪并萘啶二酮类化合物的制备方法及其中间体 |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025256521A1 (zh) * | 2024-06-11 | 2025-12-18 | 上海济煜医药科技有限公司 | 作为kras抑制剂的稠合吡啶酮类化合物的制备方法、中间体及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190177338A1 (en) * | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Chemical compounds |
| WO2020156285A1 (zh) * | 2019-01-29 | 2020-08-06 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3055290B1 (en) * | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2898765T3 (es) * | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10428064B2 (en) * | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| RU2722149C1 (ru) * | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| KR20180081596A (ko) * | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) * | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US20200010479A1 (en) * | 2017-02-03 | 2020-01-09 | The University Of North Carolina At Chapel Hill | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof |
| EP3621968A1 (en) * | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| EP3842433B1 (en) * | 2018-01-19 | 2023-11-01 | Medshine Discovery Inc. | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| CA3098574A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CN113396147B (zh) * | 2019-05-31 | 2024-06-18 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| JP7601869B2 (ja) * | 2019-10-30 | 2024-12-17 | ▲勁▼方医▲薬▼科技（上海）有限公司 | 置換された複素環－環系化合物、その調製方法及び医薬への応用 |
-
2020
- 2020-09-21 WO PCT/CN2020/116510 patent/WO2021052499A1/zh not_active Ceased
- 2020-09-21 US US17/761,983 patent/US20220389029A1/en active Pending
- 2020-09-21 CA CA3155066A patent/CA3155066A1/en active Pending
- 2020-09-21 MX MX2022003401A patent/MX2022003401A/es unknown
- 2020-09-21 CN CN202410656034.XA patent/CN118619971A/zh active Pending
- 2020-09-21 CN CN202310905052.2A patent/CN116947885B/zh active Active
- 2020-09-21 AU AU2020350745A patent/AU2020350745B2/en active Active
- 2020-09-21 PH PH1/2022/550681A patent/PH12022550681A1/en unknown
- 2020-09-21 KR KR1020227013103A patent/KR20220086573A/ko active Pending
- 2020-09-21 JP JP2022517446A patent/JP7642619B2/ja active Active
- 2020-09-21 CN CN202411842480.6A patent/CN119462689A/zh active Pending
- 2020-09-21 CN CN202411842482.5A patent/CN119591618A/zh active Pending
- 2020-09-21 TW TW109132517A patent/TWI761961B/zh active
- 2020-09-21 CN CN202080078771.6A patent/CN114728968B/zh active Active
- 2020-09-21 EP EP20865331.1A patent/EP4043464A4/en active Pending
- 2020-09-21 BR BR112022005193A patent/BR112022005193A2/pt unknown
-
2022
- 2022-03-17 IL IL291467A patent/IL291467B1/en unknown
- 2022-03-18 CL CL2022000666A patent/CL2022000666A1/es unknown
- 2022-04-12 CO CONC2022/0004686A patent/CO2022004686A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190177338A1 (en) * | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Chemical compounds |
| WO2020156285A1 (zh) * | 2019-01-29 | 2020-08-06 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022005193A2 (pt) | 2022-08-16 |
| AU2020350745A1 (en) | 2022-04-07 |
| CN119462689A (zh) | 2025-02-18 |
| CA3155066A1 (en) | 2021-03-25 |
| CN118619971A (zh) | 2024-09-10 |
| WO2021052499A1 (zh) | 2021-03-25 |
| EP4043464A4 (en) | 2023-10-04 |
| MX2022003401A (es) | 2022-07-13 |
| CO2022004686A2 (es) | 2022-07-08 |
| TWI761961B (zh) | 2022-04-21 |
| CN116947885A (zh) | 2023-10-27 |
| JP2022549171A (ja) | 2022-11-24 |
| PH12022550681A1 (en) | 2023-04-24 |
| CL2022000666A1 (es) | 2022-10-14 |
| US20220389029A1 (en) | 2022-12-08 |
| IL291467A (en) | 2022-05-01 |
| IL291467B1 (en) | 2026-03-01 |
| KR20220086573A (ko) | 2022-06-23 |
| EP4043464A1 (en) | 2022-08-17 |
| TW202126654A (zh) | 2021-07-16 |
| CN114728968B (zh) | 2024-11-15 |
| CN119591618A (zh) | 2025-03-11 |
| CN116947885B (zh) | 2026-01-23 |
| CN114728968A (zh) | 2022-07-08 |
| JP7642619B2 (ja) | 2025-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020350745B2 (en) | Fused pyridone compound, and preparation method therefor and use thereof | |
| JP7280928B2 (ja) | 脱ユビキチン化酵素（ｄｕｂ）阻害剤としてのスピロ縮合ピロリジン誘導体 | |
| TWI881008B (zh) | 嗒基-噻唑甲醯胺化合物 | |
| EP3761980B1 (en) | Amino acid compounds and methods of use | |
| US12421249B2 (en) | Inhibitors of APOL1 and methods of using same | |
| US20230118795A1 (en) | Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof | |
| CA3246028A1 (en) | KIF18A INHIBITOR | |
| CN109863151B (zh) | 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物 | |
| CN112689638A (zh) | 作为lsd1抑制剂的环丙胺类化合物及其应用 | |
| TWI354669B (en) | Pyrimidone compound | |
| WO2021170631A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| WO2021170627A1 (en) | Difluorocyclohexyl derivatives as il-17 modulators | |
| CN114286822A (zh) | 作为pd-1/pd-l1小分子抑制剂的化合物及其应用 | |
| US20250188079A1 (en) | Inhibiting cyclic amp-responsive element-binding protein (creb) | |
| KR20240021923A (ko) | Parp7 억제제 및 이의 용도 | |
| US12122787B2 (en) | Fused pyridone compound, and preparation method therefor and use thereof | |
| EA051763B1 (ru) | Конденсированное пиридоновое соединение, способ его получения и его применение | |
| HK40068840A (en) | Fused pyridone compound, preparation method therefor and use | |
| HK40068189A (en) | Compound as small molecule inhibitor pd-1/pd-l1 and application thereof | |
| HK40068840B (zh) | 稠合吡啶酮类化合物及其制备方法和应用 | |
| HK40037094A (en) | Amino acid compounds and methods of use | |
| HK40037094B (en) | Amino acid compounds and methods of use | |
| HK40044282A (en) | Amino acid compounds and methods of use | |
| JP2020527605A (ja) | イソキノリニルスルホニル誘導体およびその使用 |